Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Oct 21 - Oct 26
Onoue S, Yamada S, Yajima T
If results are positive, Eli Lilly will likely submit a New Drug Application in late 2026 or early 2027
Despite these promising results, MK-0493 did not show clinically significant efficacy in obese human participants at either a 400 mg PO dose or a step-titrated 800 mg PO dose ( ad libitum energy intake model, MK-0493 was associated with a small and marginally significant reduction in total 24-hour energy intake, whereas 30 mg of sibutramine (positive control) was associated with a significant reduction in total 24-hour energy intake ( While MK-0493 did not achieve clinical success, an analysis of these studies can provide potential rationale for failure
Patrick J
US$ 24.60
US$ 29.14
US$ 21.43
US$ 25.51
US$ 26.78
